
---
title: '中信证券：抗原检测海外存刚需 新冠防疫国内新手段'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=7984'
author: 证券时报网
comments: false
date: Sun, 20 Mar 2022 16:11:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=7984'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS600030" style="color: #2f67d1;text-decoration: none;" code="600030" target="_blank">中信证券</a>研报指出，海外疫情仍处于反复阶段，抗原检测后续需求延续性存较大市场预期差，欧洲市场有望逐步演绎“量价齐升”逻辑；预计美国市场订单将持续有序落地，且头部供应商拿单优势已逐步验证；此外，国内市场正式放开抗原自测，亦将带来全新增量市场，尤其短期预计各地将有批量补库存需求。在此背景下，优先看好产能有保障、技术有优势、销售有经验、产品有验证的抗原自测产品主流供应商，后续也有望凭借固有优势逐步切入国内全新增量市场。其次，看好率先获得国内抗原检测产品认证的供应商及其余防疫物资供应商。重点推荐<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS688298" style="color: #2f67d1;text-decoration: none;" code="688298" target="_blank">东方生物</a>，建议关注<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS688075" style="color: #2f67d1;text-decoration: none;" code="688075" target="_blank">安旭生物</a>、<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300482" style="color: #2f67d1;text-decoration: none;" code="300482" target="_blank">万孚生物</a>、<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300677" style="color: #2f67d1;text-decoration: none;" code="300677" target="_blank">英科医疗</a>。</p>

                  
</div>
            